Skip to main content

Aeterna Zentaris Inc(AEZS-T)
TSX

Today's Change
Real-Time Last Update

Closing Bell: Aeterna Zentaris Inc up on Tuesday (AEZS)

Automated Summaries - The Globe and Mail - Tue Mar 26, 4:02PM CDT

Today during trading, shares of Aeterna Zentaris Inc opened at $2.71 and closed at $2.77. It traded at a low of $2.70 to a high of $2.77.

The price raised 0.73% from the previous day's close of $2.75.

During the day across North America, the TSX Composite closed -0.19% at 21942.28, the S&P 500 closed -0.31% at 5218.19, the Dow Jones Industrial Average closed -0.41% at 39313.64 and the Nasdaq Composite closed -0.27% at 16384.47.

Aeterna Zentaris Inc has listed on the Toronto Stock Exchange (TSX) under the ticker AEZS.

A total of 800 shares was traded during the last trading day, with total trades of 6, while having an average volume of 1,325 over the last 5-days.

The TSX overall saw 2,365 price advancers against 2,885 declines and 121 unchanged.

During the prior 52 weeks, AEZS.TO has traded as high as $4.48 (April 25,2023) and low as $1.91 (November 01,2023). Moreover, in the last 52 weeks, Aeterna Zentaris Inc's shares have dipped -23.06 percent, while in 2024, they have advanced 7.78%.

It announced a 1237.50 dividend on July 22/99, with an August 11/99 ex-date and January 01/70 pay day.

Following today's trading, Aeterna Zentaris Inc has a market capitalization of $13.35 million on a float of 4,856 shares outstanding. Its annual EPS is $-4.81.

Aeterna Zentaris Inc is a TSX Biotechnology company headquartered in Toronto, CAN.

Aeterna Zentaris Inc is holding an average recommendation of "Strong Buy" from 1.00 analysts according to Zacks. From those 1 analysts, 1 have buy ratings.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..

More from The Globe